Lee J.-J.Lin L.-Y.Hsieh S.-W.Chang T.-A.SHIANN-TANG JOULiu C.C.-H.Chen M.-T.2021-01-052021-01-0520120148-7043https://www.scopus.com/inward/record.uri?eid=2-s2.0-84870199163&doi=10.1097%2fSAP.0b013e3182749b5c&partnerID=40&md5=e7adc9ea9ec51823dd78f815cea48a01https://scholars.lib.ntu.edu.tw/handle/123456789/537736Kasabach-Merritt phenomenon (KMP) is a rare and life-threatening disease of vascular tumor combined with severe consumptive coagulopathy. Currently, there is no established effective treatment of KMP. In this case series, from 2006 to 2008, we treated 6 pediatric patients with newly diagnosed KMP using intralesional corticosteroid injections. The severity and progression of the disease were closely monitored with clinical photographs, blood sampling, and tissue biopsies. The 6 pediatric patients (5 females and 1 male) showed tumor regression after treatments. All coagulopathies were corrected. The average duration of treatment was 3.8 months. Complete tumor regression was observed at approximately 3 years. Treatment was complicated in 1 patient with transient growth retardation. Treatment based on intralesional corticosteroid injections is effective for pediatric patients with KMP. Treatment-associated complications seemed to be reversible and acceptable by severity level. Copyright ? 2012 by Lippincott Williams & Wilkins.corticosteroids; hemangioma; kaposiform hemangioendothelioma; Kasabach-Merritt phenomenon; tufted angioma[SDGs]SDG3corticosteroid; article; female; human; infant; intralesional drug administration; Kasabach Merritt syndrome; male; newborn; remission; Adrenal Cortex Hormones; Female; Humans; Infant; Infant, Newborn; Injections, Intralesional; Kasabach-Merritt Syndrome; Male; Remission Inductionjournal article10.1097/SAP.0b013e3182749b5c231543332-s2.0-84870199163